Cerliponase alfa

Drug Profile

Cerliponase alfa

Alternative Names: BMN 190; Brineura

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Enzymes; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Tripeptidyl peptidase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neuronal ceroid lipofuscinosis

Most Recent Events

  • 21 Apr 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of cerliponase alfa for Neuronal ceroid lipofuscinosis in European Union
  • 09 Nov 2016 BioMarin initiates an expanded access programme for Neuronal ceroid lipofuscinosis (In adolescents, In children) in United Kingdom and Italy (Intracerebral) before November 2016 (NCT02963350)
  • 12 Sep 2016 Planned Prescription Drug User Fee Act (PDUFA) date for Neuronal ceroid lipofuscinosis (In adolescents, In children) in USA (Intracerebral) is 2017-04-27
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top